RISE Integrated Mental Health in York, Maine, offers ketamine therapy for trauma and depression, attracting patients ...

When Matt Thierfelder began his career as a Vancouver firefighter in 1994, the weight of unspoken rules hung over him: Don’t show weakness and don’t be vulnerable.

Research on synthetic psychedelics progresses, and there's hope to prove psilocybin safe and effective in intractable ...

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the ...

Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE Therapeutics, is expected ...

Johnson & Johnson's Spravato therapy for treatment-resistant depression (TRD) hasn't made the impact the company hoped for in the market, and it is looking to new clinical results to accelerate ...

Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.